Evidence map›Paper›PMID 26125142›Full record

ArticleAIDS (London, England)2015

Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study.

Mathias Bruyand, Fabien Le Marec, Armelle Lavole, Karen Leffondre, Jean Philippe Spano, Vincent Le Moing, Pierre Tattevin, Laura March, Jacques Cadranel, Fabrice Bonnet and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. The Role of Respiratory Microbiota in Lung Cancer.International journal of biological sciences · 2021
    Review
  2. Lung cancer in persons with HIV.Current opinion in HIV and AIDS · 2017
    Review
  3. Non-infectious Pulmonary Diseases and HIV.Current HIV/AIDS reports · 2016
    Review
  4. Lung Malignancies in HIV Infection.Seminars in respiratory and critical care medicine · 2016
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Mathias BruyandaCentre de recherche Inserm U897 Epidémiologie et Biostatistique, Bordeaux bInstitut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université de Bordeaux, Bordeaux cService de Pneumologie AP-HP, Hôpital Tenon F75970 and Sorbonne Université, UPMC Univ Paris 06, GRC n-04, Theranoscan, Paris dCHU Pitié-Salpétrière, Service d'oncologie médicale, Paris eCHU de Montpelier/UMI 233 'TransVIHMI' IRD/Université Montpellier 1, Montpellier fCHU Pontchaillou, Service des maladies infectieuses, Rennes gINSERM U912, Marseille hINSERM UMR-S 1136, Paris iSorbonnes Universites, UPMC Univ Paris 06, UMR-S 1136, F-75013, Paris, France.
Fabien Le Marec
Armelle Lavole
Karen Leffondre
Jean Philippe Spano
Vincent Le Moing
Pierre Tattevin
Laura March
Jacques Cadranel
Fabrice Bonnet
Marguerite Guiguet
Université de Bordeaux · FRSorbonne Université · FRInserm · FRHôpital Pontchaillou · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed at assessing in persons living with HIV with a smoking history an association between lung cancer risk and protease inhibitors exposure, especially ritonavir.

designA nested case-control study was conducted within the ANRS CO4 FHDH, CO3 Aquitaine and Tenon's Hospital Cohorts.

methodsCases and controls were eligible if they were ex-smokers or current smokers at the index date, and had a CD4 cell count reported in the year preceding the index date. Cases were incident cases of lung cancer diagnosed between 1 January 2000 and 31 December 2011. All cancer cases were validated and histological types identified when available. Three controls were randomly selected by incidence density sampling using calendar time as the time axis, with individual matching on cohort, age (± 5 years), route of HIV acquisition, sex and hospital. Analyses were performed using conditional logistic regression adjusted for nadir CD4 cell count and smoking status. Ritonavir and protease inhibitors exposures were represented in separate models using categorical variables (never exposed, ever exposed). Several sensitivity analyses were performed.

resultsThis study performed in 1447 persons living with HIV with a smoking history (383 lung cancer cases and 1064 control patients) did not evidence any association between lung cancer risk and protease inhibitors exposure including ritonavir.

conclusionThese results suggest that the risk of lung cancer is not influenced by pharmacologically induced P450 cytochrome protease inhibitors inhibition among smokers or ex-smokers.

Indexed as

AdultCase-Control StudiesCohort StudiesFemaleHIV InfectionsHIV Protease InhibitorsHumansLung NeoplasmsMaleMiddle AgedRisk AssessmentRisk FactorsRitonavirSmokingHIV Protease InhibitorsRitonavir

Identifiers

PMID26125142
OpenAlexW2027810746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.